The Role of Magnetic Resonance Imaging in Cardiomyopathies in the Light of New Guidelines: A Focus on Tissue Mapping
Authors:
- Cinzia ForleoCinzia Forleo
- Maria Cristina CarellaMaria Cristina Carella
- Paolo BasilePaolo Basile
- Donato MandunzioDonato Mandunzio
- Giulia GrecoGiulia Greco
- Gianluigi NapoliGianluigi Napoli
- Eugenio CarulliEugenio Carulli
- Marco Maria DicoratoMarco Maria Dicorato
- Ilaria DentamaroIlaria Dentamaro
- Vincenzo Ezio SantobuonoVincenzo Ezio Santobuono
- Riccardo MemeoRiccardo Memeo
- Michele Davide LatorreMichele Davide Latorre
Open Access
- 29 April 2024
- journal article
- review article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (9) , 2621
Abstract
Cardiomyopathies (CMPs) are a group of myocardial disorders that are characterized by structural and functional abnormalities of the heart muscle. These abnormalities occur in the absence of coronary artery disease (CAD), hypertension, valvular disease, and congenital heart disease. CMPs are an increasingly important topic in the field of cardiovascular diseases due to the complexity of their diagnosis and management. In 2023, the ESC guidelines on cardiomyopathies were first published, marking significant progress in the field. The growth of techniques such as cardiac magnetic resonance imaging (CMR) and genetics has been fueled by the development of multimodal imaging approaches. For the diagnosis of CMPs, a multimodal imaging approach, including CMR, is recommended. CMR has become the standard for non-invasive analysis of cardiac morphology and myocardial function. This document provides an overview of the role of CMR in CMPs, with a focus on tissue mapping. CMR enables the characterization of myocardial tissues and the assessment of cardiac functions. CMR sequences and techniques, such as late gadolinium enhancement (LGE) and parametric mapping, provide detailed information on tissue composition, fibrosis, edema, and myocardial perfusion. These techniques offer valuable insights for early diagnosis, prognostic evaluation, and therapeutic guidance of CMPs. The use of quantitative CMR markers enables personalized treatment plans, improving overall patient outcomes. This review aims to serve as a guide for the use of these new tools in clinical practice.Keywords
All Related Versions
This publication has 111 references indexed in Scilit:
- Non-Dilated Left Ventricular Cardiomyopathy vs. Dilated Cardiomyopathy: Clinical Background and OutcomesESC Heart Failure, 2024
- Tracking Treatment Response in Cardiac Light-Chain Amyloidosis With Native T1 MappingJAMA Cardiology, 2023
- Cardiac magnetic resonance imaging of arrhythmogenic cardiomyopathy: evolving diagnostic perspectivesEuropean Radiology, 2022
- Cardiac magnetic resonance T2 mapping and feature tracking in athlete’s heart and HCMEuropean Radiology, 2020
- T1 mapping and cardiac magnetic resonance feature tracking in mitral valve prolapseEuropean Radiology, 2020
- Cardiac T2* mapping: Techniques and clinical applicationsJournal of Magnetic Resonance Imaging, 2019
- Biventricular myocardial strain analysis using cardiac magnetic resonance feature tracking (CMR-FT) in patients with distinct types of right ventricular diseases comparing arrhythmogenic right ventricular cardiomyopathy (ARVC), right ventricular outflow-tract tachycardia (RVOT-VT), and Brugada syndrome (BrS)Clinical Research in Cardiology, 2019
- Long‐term improvement in cardiac magnetic resonance in β‐thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac functionAmerican Journal of Hematology, 2018
- Insights into Mildly Dilated Cardiomyopathy: Temporal Evolution and Long-Term PrognosisEuropean Journal of Heart Failure, 2016
- Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor studyJournal of Magnetic Resonance Imaging, 2016